Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tezampanel vs. triptans

Tezampanel vs. triptans

Compound [target] Study Dose Patient no. 2 hr headache response
Tezampanel [AMPA/kainate receptor] (TorreyPines) Ph IIb 100 mg SC 77 57% (p=NS)
70 mg SC 74 64% (p=NS)
40 mg SC 78 78% (p=0.033)
Placebo 75 59%
Ph

Read the full 428 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE